OR9 Stock Overview
A medical technology company, engages in the design, manufacturing, and marketing of sterile implants and single-use sterile surgical instruments for the treatment of spinal surgery.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Safe Orthopaedics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0002 |
| 52 Week High | €0.27 |
| 52 Week Low | €0.0001 |
| Beta | 0.90 |
| 1 Month Change | 0% |
| 3 Month Change | -77.78% |
| 1 Year Change | -99.92% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| OR9 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -66.7% | 0.8% | -0.3% |
| 1Y | -99.9% | -3.3% | 4.5% |
Return vs Industry: OR9 underperformed the German Medical Equipment industry which returned -3.4% over the past year.
Return vs Market: OR9 underperformed the German Market which returned 4.3% over the past year.
Price Volatility
| OR9 volatility | |
|---|---|
| OR9 Average Weekly Movement | 255.9% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: OR9's share price has been volatile over the past 3 months.
Volatility Over Time: OR9's weekly volatility has decreased from 290% to 256% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 138 | Pierre Dumouchel | www.safeorthopaedics.com |
Safe Orthopaedics SA, a medical technology company, engages in the design, manufacturing, and marketing of sterile implants and single-use sterile surgical instruments for the treatment of spinal surgery. The company’s products portfolio includes SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies, as well as essential kit for percutaneous treatment of spinal fractures; SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems; SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. Safe Orthopaedics SA was founded in 2010 and is headquartered in Eragny-sur-Oise, France.
Safe Orthopaedics SA Fundamentals Summary
| OR9 fundamental statistics | |
|---|---|
| Market cap | €4.48k |
| Earnings (TTM) | -€6.96m |
| Revenue (TTM) | €5.86m |
0.0x
P/S Ratio0.0x
P/E RatioIs OR9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OR9 income statement (TTM) | |
|---|---|
| Revenue | €5.86m |
| Cost of Revenue | €1.76m |
| Gross Profit | €4.11m |
| Other Expenses | €11.07m |
| Earnings | -€6.96m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 70.06% |
| Net Profit Margin | -118.84% |
| Debt/Equity Ratio | -609.1% |
How did OR9 perform over the long term?
See historical performance and comparison